Navigation Links
Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
Date:7/22/2010

KING OF PRUSSIA, Pa., July 22 /PRNewswire/ -- Recovering unnecessarily lost patient information is now a viable reality.  Lost to follow up (L2FU) rates in clinical research trials can range from 20- 60%. As a result, patients who drop from a clinical trial and 'go missing' can impart a major set-back in pharmaceutical research. Failure to contact patients and obtain final closure data, or bring them back into the clinical trial (if the protocol allows) results in study delays, increased patient recruitment costs, compromised study data, and in some cases an insufficient amount of information to prove the safety and efficacy of a drug.

Consequently, regulatory agencies such as the FDA, are requesting that clinical trial sponsors perform comprehensive follow up measures as part of a clinical trial's due diligence efforts or during the conduct of long term safety surveillance studies to monitor patient outcomes.

L2FU, a company specializing in helping clinical trial sites and biopharma companies to locate, contact and collect data from patients deemed 'Lost to Follow-Up', is building a portfolio of successes and an industry reputation for its quality work. The L2FU team proudly reports its latest successful recovery of 100% of a recent study's lost clinical trial patients. This was achieved in only one month to meet a truncated timeline.  The client, a leading integrated managed care organization, with operations in a number of major states across the US and nearly 10 million patient members, required the information rapidly.

The L2FU team worked diligently to recover the lost patients, who were located in other states while acquiring new addresses. "Finding these lost patients several years after their clinical trial participation goes a long way to ensuring that our client's study meets its primary endpoints, and that all of their data is accepted by the Food and Drug Administration (FDA)," noted Bernard Hall, L2FU's manager and main point of contact.

L2FU works closely with clinical research sites and data managers at clinical research organizations (CROs) and biopharmaceutical companies to transmit collected patient data in a secure manner; adhering to HIPAA regulations for privacy and data security. The L2FU team is experienced in proactively recovering lost study subjects and sensitively communicating with patients and their families. Team members are trained on the procedures required for the licensed access to many databases containing millions of vital records.

Employing L2FU to manage lost patients allows already overworked study coordinators to focus their time on active patients in the study, and the L2FU team provides clinical trial sponsors the reassurance that missing patients and required outcome data will be accounted for.

L2FU is part of MediciGlobal, a global leader in the recruitment and retention of patients for clinical trials. With more than 20 years of clinical trials experience in patient recruitment-retention, MediciGlobal is a company dedicated to the recruitment-retention and reconnection of patients for clinical trials.  For more information on L2FU visit http://www.L2FU.com or call Bernard Hall at 484-674-6816.


'/>"/>
SOURCE MediciGlobal
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MabVax Therapeutics Initiates Phase II Clinical Trial of Vaccine to Prevent Recurrent Sarcoma
2. Ampio Pharmaceuticals Announces Initiation of Phase II Clinical Trial of Optina™
3. Cara Therapeutics Secures $15 Million Series D Financing to Continue Clinical Development of CR845
4. Medical Device Consultants, Inc. and Clinical Development & Support Services Ltd Announce Strategic Partnership
5. Innovative Partnership Helps Improve Medical Research by Optimizing Clinical Trials
6. Pfizer Suspends Chronic Pain Studies in Tanezumab Clinical Trial Program; Some Studies Continue in Areas of Unmet Medical Need
7. Noscira Presents Results of Phase IIa Clinical Trial with Nypta(R) (Tideglusib) on Alzheimers Disease at International Conference on Alzheimers Disease (ICAD)
8. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
9. ISTA Pharmaceuticals Initiates Clinical Development of Bepotastine Besilate Nasal Spray for the Treatment of Symptoms Associated with Seasonal Allergic Rhinitis
10. Innocoll Submits SPA for Cogenzia(TM) Phase III Clinical Trials for the Adjuvant Treatment of Diabetic Foot Infections
11. Pfizer to Present More Than 40 Abstracts on Pre-Clinical, Clinical and Outcomes Research at Alzheimers Association International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... , March 23, 2017 ... Piramal Enterprises Limited, gibt die Ernennung von ... PPS bietet seinen globalen Pharmazeutikkunden eine einmalige ... eine wichtige Rolle für das erfolgreiche Wachstum ... kaufmännischer Leiter wird Herr Needleman dafür verantwortlich ...
(Date:3/23/2017)... March 23, 2017 Pre-market today, Stock-Callers.com ... PLC (NYSE: AGN), Horizon Pharma PLC (NASDAQ: HZNP), and Evoke ... stocks are part of the Healthcare sector, which was slightly ... 2017, with the NYSE Health Care Index adding about 0.1% ... S&P 500 also were up nearly 0.1% as a group. ...
(Date:3/23/2017)... 23, 2017 AbbVie, a global biopharmaceutical company, ... Julianne Hough is helping to raise awareness ... Know about ME in EndoMEtriosis . "   The ... to learn about and understand endometriosis, a disease affecting ... to address their symptoms with a healthcare professional.  Despite ...
Breaking Medicine Technology:
(Date:3/23/2017)... ... March 23, 2017 , ... GeBBS Healthcare ... Assurance, at HCCA’s 21st annual Compliance Institute on March 26-28 in National Harbor, ... for all medical chart types with a comprehensive set of features including built-in ...
(Date:3/23/2017)... ... ... Woman Be Ye Healed-Passing On A Legacy”: a call to heal the wounded Church. ... author, Desiree M Webb, a registered nurse, minister of music, speaker, songwriter, recording artist, ... husband, Paul, for over twenty-nine years. Desiree enjoys writing, beach trips, ministering in ...
(Date:3/23/2017)... , ... March 23, 2017 , ... ... the existence of God. “A Respectful Response To Atheist Manifesto” is the creation ... married to his wife, Nancy, for sixty years. He holds graduate degrees from ...
(Date:3/23/2017)... ... March 23, 2017 , ... Vortex Biosciences, provider ... protein expression in circulating tumor cells using microfluidic western blotting” in Nature Communications ... Vortex technology to capture CTCs and a microfluidic single-CTC resolution Western ...
(Date:3/22/2017)... ... March 23, 2017 , ... Catalent Pharma Solutions, ... biologics and consumer health products, today announced that it had won the ‘Clinical ... at the Suntec Singapore International Exhibition & Convention Centre, Singapore. The award was ...
Breaking Medicine News(10 mins):